Date: 2014-09-23
Type of information: Interim results
phase:
Announcement: interim results
Company: Acceleron Pharma (USA - MA)
Product: dalantercept
Action
mechanism: Dalantercept is a first-in-class angiogenesis inhibitor with a mechanism distinct from VEGF inhibition. Dalantercept is a soluble form of the activin receptor-like kinase 1 (ALK1) that binds to the TGF-β superfamily members BMP9 and BMP10 and prevents these proteins from signaling through ALK1. ALK1 is expressed on activated blood vessel cells and plays critical roles in the formation and maturation of blood vessels. Dalantercept inhibits ALK1 signaling, which is required for the development of mature, functional vasculature.
Disease: ovarian cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On September 23, 2014, Acceleron Pharma, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, announced results from an interim report for a two-part clinical study sponsored by the Gynecology Oncology Group evaluating dalantercept as monotherapy in patients with recurrent or persistent epithelial ovarian cancer. The study design required at least 7 of 30 patients enrolled in part one of the study to be progression free for greater than six months in order to trigger the enrollment of approximately an additional 30 patients for part two of this study. In part one of the study, 6 patients were progression free without receiving non-protocol therapy for greater than six months. Based on these results, patients will not be enrolled in the second part of the trial.
“We are conducting internally run clinical studies in those indications where the supporting science tells us that dalantercept has the best chance of benefitting patients, such as our ongoing studies of dalantercept used in combination with approved angiogenesis inhibitors to treat patients with kidney and liver cancer. However, we also welcome collaborations with investigators and collaborative groups to conduct externally sponsored clinical trials, such as this monotherapy ovarian cancer study, that complement our core development programs. We believe this is an efficient approach to broadly explore the potential benefits of dalantercept in a variety of cancers,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron.
